The effect of oral nutritional supplementation combined with probiotics on the liver function and intestinal microflora in lung cancer chemotherapy patients through the gut-liver axis.
- 2025-03-24
- Scientific reports 15(1)
- Xuelong Li
- Wenjing Gong
- Kun Tang
- Jingwen Kang
- Fubo Song
- Yan Wang
- PubMed: 40128340
- DOI: 10.1038/s41598-025-95005-x
Study Design
- Type
- Randomized Controlled Trial (RCT)
- Sample size
- n = 113
- Population
- 113 patients with lung cancer
- Methods
- Routine hospitalization diet and oral nutrition supplement; intervention group received probiotic supplementation, control group received placebo; lasted for 21 days
- Duration
- 21 days
- Funding
- Unclear
- Large Human Trial
- Rigorous Journal
The role of gut microbiota in cancer treatment research is receiving increasing attention. This study aims to evaluate the oral nutritional supplementation combined with probiotics on the liver function and intestinal microflora of lung cancer chemotherapy patients. An evaluation was conducted involving 113 patients with lung cancer, who were given routine hospitalization diet and oral nutrition supplement (ONS). The intervention group received probiotic supplementation, while the control group received placebo. It lasted for 21 days. The primary endpoint was the changes in liver function and intestinal microflora. Secondary endpoints included nutrition and immune status, and blood lipids. Compared with the control group, there were differences in the serum levels of ALT, AST, endotoxin and the amount of gut microbiota in the intervention group (P < 0.05). However, no significant changes were found in nutrition, immune, and the blood lipids status. ONS combined with probiotics could improve the liver function and gut microbiota status of lung cancer chemotherapy patients. We speculate that this may be due to the role of supplementing probiotics in regulating the gut-liver axis.